Table 5. Grade ≥ 3 TEAEs occurring in at least five patients (safety population).

Bolded text indicates TEAEs of interest for chemotherapy.

^aCombines the preferred terms neutropenia and neutrophil count decreased.

^bCombines the preferred terms anemia and hemoglobin decreased.

^cCombines the preferred terms thrombocytopenia and platelet count decreased

^dCombines the preferred terms leukopenia and white blood cell count decreased.

Abbreviations: cFOLFOXIRI‐BEV, concurrent 5‐fluorouracil/leucovorin/oxaliplatin/irinotecan plus bevacizumab; FOLFOX‐BEV, 5‐fluorouracil/leucovorin/oxaliplatin plus bevacizumab; sFOLFOXIRI‐BEV, sequential 5‐fluorouracil/leucovorin/oxaliplatin/irinotecan plus bevacizumab; TEAE, treatment‐emergent adverse event.